Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks ; volume:24 ; number:1 ; day:29 ; month:7 ; year:2024 ; pages:1-10 ; date:12.2024
BMC infectious diseases ; 24, Heft 1 (29.7.2024), 1-10, 12.2024
- Creator
-
Mulindwa, Frank
Schwarz, Jean-Marc
Brusselaers, Nele
Nabwana, Martin
Bollinger, Robert
Buzibye, Allan
Amutuhaire, Willington
Yendewa, George
Odongpiny, Eva Laker Agnes
Kiguba, Ronald
Castelnuovo, Barbara
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12879-024-09655-9
- URN
-
urn:nbn:de:101:1-2410132129293.747477996205
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mulindwa, Frank
- Schwarz, Jean-Marc
- Brusselaers, Nele
- Nabwana, Martin
- Bollinger, Robert
- Buzibye, Allan
- Amutuhaire, Willington
- Yendewa, George
- Odongpiny, Eva Laker Agnes
- Kiguba, Ronald
- Castelnuovo, Barbara
- SpringerLink (Online service)
Other Objects (12)
Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir
Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
Aberrant intestinal microbiota in individuals with prediabetes
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV
Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir
Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
Aberrant intestinal microbiota in individuals with prediabetes
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV
Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir
Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
Aberrant intestinal microbiota in individuals with prediabetes
Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV
Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic